Last Updated on December 23, 2020 by The Health Master
Lupin announced it has received approval for its Rufinamide Oral Suspension, 40 mg/mL, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.
Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients one year of age and older, and in adults.
Rufinamide Oral Suspension, 40 mg/ mL (RLD: Banzel) had estimated annual sales of $124.5 million in the US (IQVIA MAT September 2020).
Also read | India to produce 300 million Sputnik V vaccines